Crossmark

Osteoporosis therapy in patients with inflammatory rheumatic diseases and osteonecrosis of the jaw

Crossref DOI link: https://doi.org/10.1007/s00393-019-0606-y

Published Online: 2019-02-22

Published Print: 2020-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Schwaneck, E. C.

Streit, A.

Krone, M.

Hartmann, S.

Müller-Richter, U.

Kübler, A. C.

Gadeholt, O.

Schmalzing, M.

Tony, H.-P.

Brands, R. C.
License Information

Text and Data Mining valid from 2019-02-22
More Information

Article History

First Online: 22 February 2019

Compliance with ethical guidelines

:

: E.C. Schwaneck, O. Gadeholt, M. Schmalzing, and H.‑P. Tony have received speaker’s fees, travel grants, research funding, or compensation for consultations or board memberships from Roche, Chugai, MSD, UCB, Baxalta (Shire/Takeda), CSL Behring, AbbVie, Janssen, Lilly, Pfizer, Celgene, and Novartis. A. Streit, M. Krone, S. Hartmann, U. Müller-Richter, A. C. Kübler, and R. C. Brands declare that they have no competing interests.

: This article does not contain any studies with human participants or animals performed by any of the authors.